We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Lipoxen | LSE:LPX | London | Ordinary Share | GB00B08NWV55 | ORD 0.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 7.875 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMLPX Lipoxen PLC 26 May 2010 ? +---------------------------------+---------------------------------+ | FOR IMMEDIATE RELEASE | 26 May 2010 | | RNS Reach | | +---------------------------------+---------------------------------+ Lipoxen plc ('Lipoxen' or 'the Company') Expansion of DNA Vaccine Patent Allowed in US Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, announces today that an expansion of its DNA Vaccine Patent ("Patent") has been allowed in the US for its ImuXen liposomal gene technology. The ImuXen technology allows the liposomal entrapment of vaccine materials, resulting in enhanced immune responses which potentially could lead to single dose immunity being achieved while reducing the side effects associated with traditional vaccines. The new Patent protects the use of a range of additional cationic lipids that can form the building molecules of Lipoxen's ImuXen liposomes. This Patent expansion strengthens and broadens Lipoxen's existing ImuXen patents which protect the co-delivery DNA and antigen and delivery of antigen alone. Commenting on these results, Scott Maguire, CEO said: "This Patent extension is important as it further protects the patent position of our gene vaccine technology. Such added protection will provide value to commercial partners seeking long term exclusivity in the vaccine market." For further information, please contact: Enquiries +------------------------------------------+--------------------+ | Lipoxen plc | +44 (0)20 7389 | | | 5015 | +------------------------------------------+--------------------+ | M. Scott Maguire, Chief Executive | | | Officer | | +------------------------------------------+--------------------+ | | | +------------------------------------------+--------------------+ | Singer Capital Markets (nominated | +44 (0)20 3205 | | adviser) | 7500 | +------------------------------------------+--------------------+ | Jeff Keating / Claes Spång | | +------------------------------------------+--------------------+ | | | +------------------------------------------+--------------------+ | Buchanan Communications | +44 (0)20 7466 | | | 5000 | +------------------------------------------+--------------------+ | Lisa Baderoon, Catherine Breen | | +------------------------------------------+--------------------+ About Lipoxen Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines. Lipoxen has three proprietary patented technology platforms: 1) PolyXen - for extending the efficacy and half life of biologic drugs 2) ImuXen - for creating new vaccines and improving existing vaccines 3) SiRNAblate - for the delivery of siRNA Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its products. Lipoxen has multiple drug and vaccine programmes in development. Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes vaccines against HIV, influenza and malaria and an exclusive license deal with Baxter Healthcare for Factor VIII. The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities. Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and management led the GBP2.9 million fundraising that the Company announced in May 2009. This fundraising was followed up by a GBP1.2 million placing in April 2010. Lipoxen, which was founded in 1997, trades on the AIM Market of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website: www.lipoxen.com. This information is provided by RNS The company news service from the London Stock Exchange END NRAQELFLBEFLBBL
1 Year Lipoxen Chart |
1 Month Lipoxen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions